Drug Search Results
More Filters [+]

Lapaquistat

Alternative Names: lapaquistat
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SQS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lapaquistat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hypercholesterolemia|Type 2 Diabetes|Dyslipidemia|Hyperlipoproteinemia Type II

Phase 2: Hypercholesterolemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-006906-41

P3

Completed

Unknown

2010-05-22

2007-001489-34

P3

Terminated

Hypercholesterolemia

2009-06-01

TAK-475_306

P3

Terminated

Hypercholesterolemia

2008-05-01

TAK-475_307

P3

Terminated

Hypercholesterolemia

2008-04-01

Recent News Events